Growth Hormone Deficiency nursing care: what to assess and what to do first

The pathophysiology in one pass

Growth hormone deficiency (GHD) means the anterior pituitary secretes too little GH, either because the pituitary itself is damaged (a tumour, radiation, trauma, or a congenital defect) or because hypothalamic GHRH signalling fails to drive it. Without adequate GH, the liver produces less insulin-like growth factor 1 (IGF-1), and IGF-1 is the hormone that actually drives linear bone growth at the epiphyseal plates.

The result is not a sudden event but a slow drift: a child who was tracking along the 50th percentile begins falling away from their own curve. That single sentence is the diagnostic clue clinicians rely on more than any absolute height number. A short child who is still parallel to a percentile line is more likely constitutionally short; a child crossing percentile lines downward over one to two years is the one worked up for GHD. Congenital GHD can present in infancy with hypoglycaemia and prolonged jaundice; acquired GHD in an older child raises suspicion for a CNS lesion until proven otherwise.

Assessment findings that matter

The single most useful nursing assessment tool is the growth chart itself, plotted consistently over time rather than read as one visit. A nurse who measures height accurately at every visit, using the same technique and ideally the same stadiometer, gives the endocrinologist the data that actually makes the diagnosis and later confirms whether treatment is working. Growth velocity, the rate of change between two plotted points, matters more than the single height value.

Physical findings support the chart: a child who is proportionately short (not just short-limbed), with a youthful, slightly chubby facial appearance, delayed dentition, and delayed bone age on X-ray relative to chronological age. Delayed puberty onset is common because GH and gonadotropin timing are linked. In infants, check for hypoglycaemia, prolonged jaundice, and micropenis in males, all classic markers of congenital GHD.

Ask about the family history and the birth history, including any pituitary or midline defects, and screen for headache, visual change, or polyuria and polydipsia, which point toward a structural pituitary lesion rather than isolated GHD.

What the exam asks about this

NCLEX-style items on GHD tend to test whether you can distinguish it from other short-stature causes, and whether you know that the diagnosis rests on a growth curve trend rather than a single measurement. Expect a question describing a child who has dropped from the 50th to below the 5th percentile over two years, asking you to identify the priority nursing action, which is almost always accurate serial height measurement and referral, not reassurance.

A second common pattern tests GH stimulation testing: know that a single low GH level is not diagnostic, because GH is secreted in pulses, so provocative testing with two agents (such as arginine, clonidine, or glucagon) is used to confirm deficiency. A third pattern tests medication teaching, particularly injection technique, timing, and the rationale for daily rather than intermittent dosing, since GH given nightly mimics natural nocturnal pulsatile secretion.

Nursing interventions in priority order

First, establish accurate baseline anthropometrics: height, weight, growth velocity, and bone age, and document them so every subsequent visit is comparable. Second, support the diagnostic workup, preparing the family for GH stimulation testing, which requires fasting and IV access, and reassuring them that testing is not painful beyond the venipuncture itself.

Third, once GH therapy is prescribed, teach injection technique directly to the parent and, as the child ages, to the child themselves: subcutaneous injection sites (abdomen, thigh, upper arm), site rotation to prevent lipoatrophy, storage of the GH pen or vial refrigerated, and administration at night to mirror physiologic secretion. Fourth, build the injection into the family's actual evening routine rather than treating it as a separate medical task, since adherence over years depends on it fitting ordinary life, not disrupting it. Fifth, monitor growth response at each follow-up and reinforce that visible catch-up growth typically takes months, not weeks, which helps families persist through the early period when results are not yet obvious.

Medications and monitoring

Recombinant human GH (somatropin) is given as a daily subcutaneous injection, most often in the evening. Monitor thyroid function periodically, since GH therapy can unmask or worsen central hypothyroidism, and monitor fasting glucose or HbA1c, since GH is a counter-regulatory hormone that can raise insulin resistance. Bone age X-rays are repeated periodically, roughly annually, to track skeletal maturation alongside height.

Watch for adverse effects: headache with vomiting (a red flag for pseudotumour cerebri, prompting immediate follow-up), hip or knee pain, and edema in the early weeks of therapy, which is usually mild and self-limiting. Teach families that GH therapy commits them to a daily injection routine that typically continues for years, until growth plates fuse or the child reaches an acceptable adult height, so realistic expectation-setting at the start protects adherence later.

When to escalate

Escalate immediately for new headache accompanied by vomiting, visual changes, or papilledema, since this can indicate pseudotumour cerebri related to GH therapy or, separately, progression of an underlying pituitary or CNS lesion. Hip or knee pain with a limp needs urgent orthopaedic evaluation, because slipped capital femoral epiphysis is a recognised complication of rapid growth on GH therapy, particularly in children who are overweight.

Also escalate any sign of adrenal insufficiency or evolving panhypopituitarism, such as unexplained fatigue, hypotension, or hypoglycaemia, since GHD frequently coexists with deficiencies of other pituitary hormones and the picture can evolve over time. Report abrupt growth arrest or a plateau on the growth chart after a period of response, as this warrants reassessment of dosing, adherence, and possible antibody formation against GH.